Evaluating Clinical Outcomes of Adjunct Rifaximin Therapy in Patients with Overt Hepatic Encephalopathy: A Prospective Randomized Study.

Objectives: This study was conducted to assess the therapeutic benefit of using rifaximin in combination with lactulose vs lactulose alone in the management of overt hepatic encephalopathy (OHE) within a tertiary care setting.

Methods: A randomized controlled trial was conducted with 132 adult patients diagnosed with decompensated liver cirrhosis and presenting with OHE of West Haven Criteria grade II or higher. Participants were randomly allocated to receive either combination therapy (CT), comprising rifaximin and lactulose, or lactulose monotherapy (LM).

Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver.

Objective: To determine the efficacy of Rifaximin in prevention of repeated episodes of hepatic encephalopathy in patients with liver cirrhosis as compared to placebo.

Study Design: Triple-blind, randomized placebo-controlled trial.

Place And Duration Of Study: Department of Gastroenterology-Hepatology, Shaikh Zayed Hospital, Lahore, from October 2012 to April 2013.